Expert Discussion: ASCO 2022
none (Source: Breast Care)
Source: Breast Care - July 8, 2022 Category: Cancer & Oncology Source Type: research
Treatment outcomes according to the EndoPredict score in ER-positive, HER2-negative early breast cancer
Purpose: To evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative(ER+/HER2 −) breast cancer according to the risk group using EndoPredict(EP) score.
Patients and Methods: Between 2015 and 2019, 207 patients with ER+/HER2− pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. EPclin score, which combines the molecular EP scor e with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.3.
Results: There were 154 and 53 patients in the EPclin...
Source: Breast Care - July 6, 2022 Category: Cancer & Oncology Source Type: research
Evaluating HEmopatch ® in Reducing Seroma-Related Complications following Axillary Lymph Node DIssection: A Pilot Study (HEIDI)
Conclusion: The application of Hemopatch ® after ALND did not lead to a clinically relevant reduction of CSS and wound complications. However, fewer Hemopatch® patients required additional outpatient clinic visits. Due to the limited amount of participants, the true value of Hemopatch® in ALND remains unclear. (Source: Breast Care)
Source: Breast Care - July 4, 2022 Category: Cancer & Oncology Source Type: research
Evaluating HEmopatch ® In reducing seroma related complications following axillary lymph node DIssection: a pilot study (HEIDI)
Purpose: Axillary lymph node dissection (ALND) is performed to treat locoregional metastatic disease in breast cancer and melanoma patients. However, it is notorious for its complications, most commonly seroma formation and its sequelae. Ample research has been done to evaluate seroma formation after ALND; these results, however, have not been conclusive. Hence, this pilot study aimed to evaluate a readily available haemostatic patch, Hemopatch ®, to assess its effect on seroma formation following ALND.
Methods: In this pilot study a prospective cohort of 20 patients receiving Hemopatch® following ALND, was compared to a...
Source: Breast Care - July 4, 2022 Category: Cancer & Oncology Source Type: research
Erratum
Breast Care (Source: Breast Care)
Source: Breast Care - June 23, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Breast Care 2022;17:346 –348 (Source: Breast Care)
Source: Breast Care - June 14, 2022 Category: Cancer & Oncology Source Type: research
Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer
Conclusion: We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.Breast Care (Source: Breast Care)
Source: Breast Care - June 3, 2022 Category: Cancer & Oncology Source Type: research
Lack of prognostic value of pre-treatment neutrophil-to-lymphocyte ratio in early breast cancer
Conclusion: We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias. (Source: Breast Care)
Source: Breast Care - June 3, 2022 Category: Cancer & Oncology Source Type: research
Metaplastic Breast Cancer: Mesenchymal subtype has worse survival outcomes
Conclusion: This study is one of the few studies presenting the survival outcomes of subtypes of MBCs. Nonetheless, it is the only study demonstrating that mesenchymal subtype had worse survival outcomes. Further studies are needed to determine the outcome of different subtypes of MBCs. (Source: Breast Care)
Source: Breast Care - June 2, 2022 Category: Cancer & Oncology Source Type: research
Prepubertal idiopathic unilateral gynecomastia: case report and literature review
Conclusion
Chromosomal and genetic testing, as well as oncological, endocrine diagnostic and tests for liver and kidney function should be performed. In case of idiopathic prepubertal gynecomastia surgery is an important part of therapy since patients suffer from their atypical and rare phenotype. (Source: Breast Care)
Source: Breast Care - May 17, 2022 Category: Cancer & Oncology Source Type: research
Prophylaxis of Neutropenia with Lipegfilgrastim in Breast Cancer Patients with Dose-Dense Chemotherapy: Results of a Noninterventional Study on Therapeutic Routine in Germany (NADENS)
Conclusion: These results suggest that primary lipegfilgrastim prophylaxis is effective and safe in clinical routine and is beneficial in primary breast cancer patients undergoing dd/idd-ETC CTx. (Source: Breast Care)
Source: Breast Care - May 11, 2022 Category: Cancer & Oncology Source Type: research
Prophylaxis of Neutropenia with Lipegfilgastrim in Breast Cancer Patients with Dose-Dense Chemotherapy – Results of a non-interventional study on therapeutic routine in Germany (NADENS)
Introduction: Non-interventional study (NIS) on application and effectiveness of primary G-CSF prophylaxis with lipegfilgrastim in primary breast cancer patients undergoing dose dense (dd) or intense dose dense (idd) chemotherapy regimen (CTx) in daily clinical practice.
Methods: Prospective, multi-center, single-arm, NIS in 41 private practices
and 27 hospitals in Germany.
Results: Data analysis of 282 patients with a mean age of 49 years (93.6% of patients (Source: Breast Care)
Source: Breast Care - May 11, 2022 Category: Cancer & Oncology Source Type: research
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
Conclusion: This paper captures the update of EBC. (Source: Breast Care)
Source: Breast Care - May 5, 2022 Category: Cancer & Oncology Source Type: research
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer (EBC): Update 2022
Conclusion: This paper captures the update of EBC. (Source: Breast Care)
Source: Breast Care - May 5, 2022 Category: Cancer & Oncology Source Type: research
The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer
Purpose: Patients with locally advanced breast cancer (LABC), should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of ...
Source: Breast Care - May 3, 2022 Category: Cancer & Oncology Source Type: research
